作者: Marc S. Rosenshein , Vernon T. Farewell , Thomas H. Price , Eric B. Larson , David C. Dale
DOI: 10.1056/NEJM198005083021904
关键词:
摘要: We analyzed the cost effectiveness of leukocyte transfusion in preventing death from infection during intensive chemotherapy for acute leukemia. Effectiveness was estimated with an odds-ratio analysis based on published results controlled studies therapeutic and prophylactic transfusion. Cost estimates were blood-bank charges throughout country. Calculations suggest that might prevent 50 to 75 per cent early deaths infection. Therapeutic would add approximately 10.9 hospital bill average leukemic patient $17.7 million annually nationwide. Prophylactic 35.2 $57.8 annually. Mean cost-effectiveness ratios $14,982 life-year $35,020 $50,029 The additional achieved rather than tran...